Search Results - "Petreni, P"

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy by Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C.E., Gnetti, L., Azzoni, C., Nizzoli, R., Bortesi, B., Rofi, E., Petreni, P., Campanini, N., Rossi, G., Danesi, R., Tiseo, M.

“…•Liquid biopsy alone could underestimate coexistence of resistance mechanisms.•T790M plasma levels should be taken into account for clinical decisions.•Low…”
Get full text

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin by Cecchin, E, Perrone, G, Nobili, S, Polesel, J, De Mattia, E, Zanusso, C, Petreni, P, Lonardi, S, Pella, N, D'Andrea, M, Errante, D, Rizzolio, F, Mazzei, T, Landini, I, Mini, E, Toffoli, G

“…Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers…”
Get full text

Aggressive Gastric Carcinoma Producing Alpha-Fetoprotein: A Case Report and Review of the Literature by Lunghi, A., Petreni, P., Romanelli, R.G., Vizzutti, F., Marra, F., Tarquini, R., Laffi, G.

“…A 65-year-old man presented to our hospital with abdominal pain, dyspepsia and anorexia. Laboratory tests showed an altered liver function and abdomen…”
Get full text

Pemetrexed maintenance therapy in advanced non-squamous NSCLC: a single institution experience by Lunghi, A., Mazzoni, F., Petreni, P., Vannini, A., Brugia, M., Calamai, V., Di Costanzo, F.

Get full text

Fast Walking And Resistance Exercise Program In Breast Cancer Survivors by Petreni, P., Lunghi, A., Mazzoni, F., Vannini, A., Rispoli, A.I., Brugia, M., Stefani, L., Petri, C., Galanti, G., Di Costanzo, F.

Get full text

Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors by Tassi, R., Perrone, G., Brugia, M., Simi, L., Petreni, P., Mori, E., Landini, I., Pazzagli, M., Mazzei, T., Mini, E., Nobili, S.

Get full text

Physical exercise and eating habits in cancer survivors by Mazzoni, F., Petreni, P., Lunghi, A., Vannini, A., Brugia, M., Mela, M.M., Stefani, L., Mascherini, G., Galanti, G., Di Costanzo, F.

Get full text

MTHFR-1298 AC is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin by Cecchin, E, Perrone, G, Nobili, S, Polesel, J, De Mattia, E, Zanusso, C, Petreni, P, Lonardi, S, Pella, N, D'Andrea, M, Errante, D, Rizzolio, F, Mazzei, T, Landini, I, Mini, E, Toffoli, G

“…Adjuvant treatment based on fluoropyrimidines (FL) Improves the prognosis of stage II/III colorectal cancer (CRC). Validated predlctlve/prognostlc biomarkers…”
Get full text

Aggressive gastric carcinoma producing alpha-fetoprotein: a case report and review of the literature by Lunghi, A, Petreni, P, Romanelli, R G, Vizzutti, F, Marra, F, Tarquini, R, Laffi, G

Get full text